- A group of over 40 healthcare, consumer and addiction-treatment advocates has sent a letter to the FDA urging the agency to withdraw its authorization of Zogenix's (ZGNX -1.8%) Zohydro opioid painkiller.
- The latest move comes after 29 state attorneys general sent a similar letter to the FDA in December, while in November, members of Congress asked the agency to review the approval.
- The fear is the potential for abuse that the narcotic pill presents, especially because of its high potency.
- "It will kill people as soon as it's released," says Andrew Kolodny of Physicians for Responsible Opioid Prescribing.
- Zohydro is set to become available in March.